• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Vincerx Pharma Inc.

    6/18/25 4:18:34 PM ET
    $VINC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $VINC alert in real time by email
    DEFA14A 1 d59162ddefa14a.htm DEFA14A DEFA14A
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    SCHEDULE 14A

    (RULE 14a-101)

    SCHEDULE 14AINFORMATION

    Proxy Statement Pursuant To Section 14(a) of the

    Securities Exchange Act of 1934

     

     

    Filed by the Registrant ☒

    Filed by a Party other than the Registrant ☐

    Check the appropriate box:

     

    ☐

    Preliminary Proxy Statement

     

    ☐

    Confidential, for use of the Commission Only (as permitted by Rule 14a-6(e)(2))

     

    ☐

    Definitive Proxy Statement

     

    ☒

    Definitive Additional Materials

     

    ☐

    Soliciting Material under§ 240.14a-12

    VINCERX PHARMA, INC.

    (Name of Registrant as Specified In Its Charter)

    (Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)

    Payment of Filing Fee (Check all boxes that apply):

     

    ☒

    No fee required

     

    ☐

    Fee paid previously with preliminary materials

     

    ☐

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(l) and 0-11

     

     
     


    [Press release issued June 18, 2025]

    Vincerx Pharma, Inc. Announces Adjournment of Special Meeting - Will Reconvene

    Meeting on July 16 , 2025 to Secure Votes Needed to Approve Dissolution Proposal

    Failure to approve Dissolution Proposal will reduce or eliminate

    any potential distributions to stockholders

    San Mateo, California, June 18, 2025 – Vincerx Pharma, Inc. today announced that the Special Meeting of Stockholders to consider a proposal to approve the liquidation and dissolution of Vincerx (the “Dissolution Proposal”), which was originally scheduled for earlier today, has been adjourned until 10:00 a.m., Pacific time, on July 16, 2025 via live audio webcast at www.virtualshareholdermeeting.com/VINC2025SM2. The adjournment will allow Vincerx more time to solicit the votes needed to approve the Dissolution Proposal.

    Vincerx is urging ALL stockholders to vote IMMEDIATELY FOR the Dissolution Proposal.

    Vincerx’s board of directors unanimously recommends that stockholders vote FOR the Dissolution Proposal and believes that approval of the Dissolution Proposal is extremely important to stockholders for a number of reasons, including the following:

     

      •  

    Preserve Possibility of Distributions. Vincerx is hopeful that cash will be available for distribution to its stockholders. However, further delays in approving the Dissolution Proposal will result in continued public company and other operating costs and expenses - reducing or eliminating what funds could remain for distribution to stockholders. Approving the Dissolution Proposal will allow Vincerx to move forward expeditiously and maximize the likelihood of a distribution to its stockholders.

     

      •  

    Recognize Potential Tax Benefits. U.S. stockholders who receive less than their tax basis in their shares could be eligible to recognize a capital loss for U.S. federal income tax purposes. Timely approval of the Dissolution Proposal will facilitate this recognition.

    “We believe it is extremely important that our stockholders vote FOR the Dissolution Proposal,” said Dr. Raquel Izumi, Acting CEO. “We understand the disappointment that all of us who are stockholders and supported the company over the years feel, but approving the Dissolution Proposal at least gives stockholders the possibility of receiving some value for their shares. Delaying approval of the Dissolution Proposal will simply result in the company continuing to incur ongoing operating costs and expenses, which will only reduce or even eliminate the likelihood that there will be any amounts left for distribution to stockholders. We therefore urge all stockholders to vote FOR the Dissolution Proposal before the reconvened meeting on July 16, 2025.”

    Every vote matters. Stockholders must ACTIVELY VOTE for their vote to count. Any delay in approving the Dissolution Proposal will result in increased expenditures and reduce the likelihood that amounts will be available for distribution to stockholders.


    Voting is quick and simple:

     

      •  

    BY PHONE: Please call Advantage Proxy, Vincerx’s proxy solicitor, toll-free at 1-877-870-8565 between the hours of 9:00 a.m. and 9:00 p.m., Eastern Time, Monday through Friday. You can also contact Advantage Proxy if you have any questions about voting.

     

      •  

    BY INTERNET: Vote by going to www.proxyvote.com and entering the control number on your proxy card or by following the instructions provided by your broker, bank, or other nominee.

    Your vote FOR the Dissolution Proposal is very important - please VOTE TODAY.

    Additional Information

    Information regarding the Dissolution Proposal, including the board of director’s reasons for recommending approval of the Dissolution Proposal, is set forth in the company’s proxy statement and supplements thereto, which have been filed with the Securities and Exchange Commission (“SEC”) and are available at the SEC’s website at www.sec.gov.

    Forward-Looking Information

    This press release contains forward-looking statements within the meaning of the federal securities laws including, but not limited to, statements about the reasons for approving, and the consequences of failing to approve, the Dissolution Proposal; the potential availability of amounts for distribution to stockholders; and the potential tax benefits to stockholders of approving the Dissolution Proposal. Forward-looking statements involve risks and uncertainties that may cause actual results or performance to differ materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to: risks involved in dissolving, liquidating, and winding down Vincerx’s business and affairs; the timing or amount of distributions, if any, to Vincerx’s stockholders; stockholder approval of the Dissolution Proposal and the timeliness of such approval; the risk that Vincerx may need to seek protection of the bankruptcy court; and the other factors discussed in Vincerx’s reports, including its Annual Report on Form 10-K for the year ended December 31, 2024, and subsequent reports filed with the SEC. All forward-looking statements are based on information available to Vincerx as of the date of this press release. Vincerx undertakes no duty or obligation to update these forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

    Contact Information:

    [email protected]

    Get the next $VINC alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $VINC

    DatePrice TargetRatingAnalyst
    1/14/2022$25.00Buy
    HC Wainwright & Co.
    12/23/2021$25.00Overweight
    Cantor Fitzgerald
    11/1/2021$24.00Outperform
    SVB Leerink
    9/13/2021$30.00Buy
    Laidlaw
    8/25/2021$26.00Buy
    B. Riley Securities
    8/13/2021$33.00 → $30.00Buy
    Chardan Capital
    More analyst ratings

    $VINC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    HC Wainwright & Co. initiated coverage on Vincerx Pharma with a new price target

    HC Wainwright & Co. initiated coverage of Vincerx Pharma with a rating of Buy and set a new price target of $25.00

    1/14/22 6:06:29 AM ET
    $VINC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cantor Fitzgerald initiated coverage on Vincerx Pharma with a new price target

    Cantor Fitzgerald initiated coverage of Vincerx Pharma with a rating of Overweight and set a new price target of $25.00

    12/23/21 6:37:41 AM ET
    $VINC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SVB Leerink initiated coverage on Vincerx Pharma with a new price target

    SVB Leerink initiated coverage of Vincerx Pharma with a rating of Outperform and set a new price target of $24.00

    11/1/21 6:31:16 AM ET
    $VINC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VINC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Haas Kevin claimed ownership of 42,776 shares (SEC Form 3)

    3 - Vincerx Pharma, Inc. (0001796129) (Issuer)

    1/6/25 4:29:47 PM ET
    $VINC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Officer Thomas Tom C

    4 - Vincerx Pharma, Inc. (0001796129) (Issuer)

    8/14/24 8:11:28 PM ET
    $VINC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Executive Officer Hamdy Ahmed Md

    4 - Vincerx Pharma, Inc. (0001796129) (Issuer)

    8/14/24 8:07:30 PM ET
    $VINC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VINC
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Vincerx Pharma Inc.

    SCHEDULE 13G/A - Vincerx Pharma, Inc. (0001796129) (Subject)

    7/29/25 5:55:43 PM ET
    $VINC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEFA14A filed by Vincerx Pharma Inc.

    DEFA14A - Vincerx Pharma, Inc. (0001796129) (Filer)

    7/16/25 4:14:14 PM ET
    $VINC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEFA14A filed by Vincerx Pharma Inc.

    DEFA14A - Vincerx Pharma, Inc. (0001796129) (Filer)

    7/7/25 4:27:01 PM ET
    $VINC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VINC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Vincerx Pharma, Inc. Announces Additional Adjournment of Special Meeting - Urges Stockholders to Vote FOR Approval of Dissolution Proposal

    Revised Potential Distribution Range of $0.03 to $0.07 per sharebased on current estimates and assumptions Failure to approve Dissolution Proposal on a timely basis will result in continued operating costs and further reduce or eliminate any potential distributions to stockholders   SAN MATEO, Calif., July 16, 2025 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (OTC:VINC) today announced that the re-convened Special Meeting of Stockholders to consider a proposal to approve the liquidation and dissolution of Vincerx (the "Dissolution Proposal"), which was originally scheduled for earlier today, has again been adjourned, this time until 10:00 a.m., Pacific time, on August 27, 2025 via li

    7/16/25 4:05:00 PM ET
    $VINC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vincerx Pharma, Inc. Urges Stockholders to Vote FOR Approval of Dissolution Proposal and Announces Potential Range for Distributions to Stockholders

    Potential Distribution Range of $0.04 to $0.08 per share of outstanding stock based on current estimates and assumptions, including timely approval of Distribution Proposal Failure to approve Dissolution Proposal will reduce or eliminate any potential distributions to stockholders   SAN MATEO, Calif., July 07, 2025 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (OTC:VINC) today announced updated information regarding the Special Meeting of Stockholders of the Company (the "Special Meeting") to consider the proposal to approve the dissolution and liquidation of the Company pursuant to the Plan of Liquidation and Dissolution (the "Dissolution Proposal"). The Special Meeting was adjourned to 10:0

    7/7/25 4:05:00 PM ET
    $VINC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vincerx Pharma, Inc. Announces Adjournment of Special Meeting - Will Reconvene Meeting on July 16, 2025 to Secure Votes Needed to Approve Dissolution Proposal

    SAN MATEO, Calif., June 18, 2025 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (OTC:VINC) today announced that the Special Meeting of Stockholders to consider a proposal to approve the liquidation and dissolution of Vincerx (the "Dissolution Proposal"), which was originally scheduled for earlier today, has been adjourned until 10:00 a.m., Pacific time, on July 16, 2025 via live audio webcast at www.virtualshareholdermeeting.com/VINC2025SM2. The adjournment will allow Vincerx more time to solicit the votes needed to approve the Dissolution Proposal. Vincerx is urging ALL stockholders to vote IMMEDIATELY FOR the Dissolution Proposal. Vincerx's board of directors unanimously recommends that stoc

    6/18/25 4:05:00 PM ET
    $VINC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VINC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Vincerx Pharma Inc.

    SC 13G - Vincerx Pharma, Inc. (0001796129) (Subject)

    11/14/24 3:39:40 PM ET
    $VINC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Vincerx Pharma Inc.

    SC 13G/A - Vincerx Pharma, Inc. (0001796129) (Subject)

    11/14/24 11:57:03 AM ET
    $VINC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Vincerx Pharma Inc.

    SC 13G/A - Vincerx Pharma, Inc. (0001796129) (Subject)

    11/13/24 8:32:26 AM ET
    $VINC
    Biotechnology: Pharmaceutical Preparations
    Health Care